Начало・Списък с акции・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Затворен

СекторЗдравеопазване

197.96 0.9

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

195.19

Максимум

202.38

Ключови измерители
By Trading Economics
Приходи	-89M -454M
EPS	-2.29
Служители	883
EBITDA	-89M -437M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+11.22% upside

Дивиденти
By Acuity
Следващи печалби	4.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	7.3B 39B
Предишно отваряне	197.06
Предишно затваряне	197.96

Настроения в новините

By Acuity

85%

15%

323 / 340 Класиране в Healthcare

REVOLUTION Medicines Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.08.2026 г., 19:36 ч. UTC

Social Media

News

Revolution Medicines Inc is trading higher as RBC Capital and Evercore ISI raise price targets, reflecting growing confidence in the company's clinical pipeline.

5.08.2026 г., 23:02 ч. UTC

Social Media

News

Revolution Medicines shares lower in after-market trading following a second-quarter loss of $644.4 million and an EPS of -$3.06, missing estimates.

4.08.2026 г., 23:06 ч. UTC

Revolution Medicines shares are lower in after-market trading, settling near Tuesday's close. The stock remains above its 20-day moving average.

3.08.2026 г., 23:26 ч. UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31.07.2026 г., 20:06 ч. UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30.07.2026 г., 22:41 ч. UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29.07.2026 г., 17:02 ч. UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28.07.2026 г., 19:02 ч. UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27.07.2026 г., 20:06 ч. UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24.07.2026 г., 18:26 ч. UTC

Social Media

News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22.07.2026 г., 18:26 ч. UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

21.07.2026 г., 17:16 ч. UTC

Revolution Medicines Inc shares are higher today, reflecting gains since Monday amid supportive market conditions and positive sentiment from Asian markets and easing oil prices.

20.07.2026 г., 17:31 ч. UTC

Social Media

News

Revolution Medicines Inc. shares are lower today despite upcoming catalysts and a projected revenue estimate of $13-15 billion by 2035. Trading volume is unusually high.

Сравнение с други в отрасъла

Ценова промяна

REVOLUTION Medicines Inc Прогноза

Ценова цел

By TipRanks

11.22% нагоре

12-месечна прогноза

Среден 219.44 USD 11.22%

Висок 291 USD

Нисък 151 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за REVOLUTION Medicines Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

18 ratings

Купи

Задържане

Продай

Според 18 анализатори, дали борсови рейтинги на REVOLUTION Medicines Inc през последните 3 месеца.

Настроение

By Acuity

323 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.